GH Research Announces Publication of Phase 2a Postpartum Depression Results
GH Research published full results from its Phase 2a open-label trial of inhaled mebufotenin (GH001) in postpartum depression, showing a mean MADRS reduction of -35.4 points. All 10 enrolled patients achieved remission within two hours of dosing, with effects sustained through Day 8 and no serious adverse events reported.
Key figures
- Drug Name
- GH001 (mebufotenin)
- Phase Of Trial
- Phase 2a
- Sample size ppd
- 10
- Remission rate ppd
- 100%
- Madrs reduction ppd
- -35.4
- Madrs reduction trd
- -15.5
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.